Lyell Immunopharma, Inc.

NasdaqGS:LYEL Stock Report

Market Cap: US$171.1m

Lyell Immunopharma Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Lynn Seely

Chief executive officer

US$2.6m

Total compensation

CEO salary percentage24.6%
CEO tenure2yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 25

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Feb 23
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Nov 09
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Aug 29
Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Aug 11
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Dec 15
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845

Oct 06

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Sep 12
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Aug 08
News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Apr 29
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Dec 31
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Sep 17
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

CEO Compensation Analysis

How has Lynn Seely's remuneration changed compared to Lyell Immunopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$204m

Jun 30 2024n/an/a

-US$210m

Mar 31 2024n/an/a

-US$228m

Dec 31 2023US$3mUS$650k

-US$235m

Sep 30 2023n/an/a

-US$190m

Jun 30 2023n/an/a

-US$209m

Mar 31 2023n/an/a

-US$182m

Dec 31 2022US$19mUS$30k

-US$183m

Sep 30 2022n/an/a

-US$258m

Jun 30 2022n/an/a

-US$237m

Mar 31 2022n/an/a

-US$263m

Dec 31 2021US$5mn/a

-US$250m

Compensation vs Market: Lynn's total compensation ($USD2.65M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Lynn's compensation has been consistent with company performance over the past year.

CEO

Lynn Seely (65 yo)

2yrs

Tenure

US$2,647,476

Compensation

Dr. Lynn Seely, MD, Ph D., serves as Lead Independent Director at Blueprint Medicines Corporation since June 2021. She serves as President and Chief Executive Officer at Lyell Immunopharma, Inc. since Dece...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Klausner
Founder & Executive Chairman4.9yrsUS$310.75k1.4%
$ 2.4m
Lynn Seely
President2yrsUS$2.65mno data
Charles Newton
Chief Financial Officer3.8yrsUS$4.32m0.0031%
$ 5.4k
Stephen Hill
Chief Operating Officer3.1yrsUS$3.11m0.0032%
$ 5.5k
Gary Lee
Chief Scientific Officer2.9yrsUS$2.23m0.0046%
$ 7.8k
Matthew Lang
Chief Business Officer1.4yrsUS$4.26mno data
Stanley Riddell
Founder & Scientific Advisor2.3yrsno datano data
Crystal Mackall
Founder & Scientific Advisor2.3yrsno datano data
Nellie Dillery
Director of Accountingno datano datano data
Ellen Rose
Senior Vice President of Communications & Investor Relationsno datano datano data
Ann Tomlin
Senior Vice President of Human Resources1.4yrsno datano data
Bryan Selby
Senior Vice President of Clinical Development Operations1.4yrsno datano data

2.3yrs

Average Tenure

54yo

Average Age

Experienced Management: LYEL's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Klausner
Founder & Executive Chairman4.9yrsUS$310.75k1.4%
$ 2.4m
Lynn Seely
President3.6yrsUS$2.65mno data
Robert Taylor Nelsen
Independent Director6.3yrsUS$286.75k0%
$ 0
William Rieflin
Independent Director4.6yrsUS$301.75k0%
$ 0
Otis Brawley
Independent Director3.7yrsUS$290.75k0%
$ 0
Elizabeth Nabel
Independent Director3.7yrsUS$293.25k0%
$ 0
Sumant Ramachandra
Directorless than a yearno datano data
Catherine Friedman
Lead Independent Director6.3yrsUS$330.25k0.12%
$ 206.2k

4.1yrs

Average Tenure

64yo

Average Age

Experienced Board: LYEL's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:29
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lyell Immunopharma, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Jason ZemanskyBofA Global Research
Salveen RichterGoldman Sachs